Hematology-Oncology Experts & Viewpoints
- Monitoring and Managing Cardiotoxicities Associated with Cancer Therapies: An Expert Interview with Dr. Pamela S. Douglas
- Why Should I Report an Adverse Drug Event?
- Retooling for an Aging America
- Should Patients With Colorectal Cancer and Nonresectable Liver Metastasis Have Surgery?
- Multimodality Approaches to a Postmastectomy Local Breast Cancer Recurrence
- Single-Agent Topotecan Still Best for Recurrent or Platinum-Resistant Ovarian Cancer
- Physicians for Sale: How Medical Professional Organizations Exploit Their Members
- Building Physician Connectivity for e-Prescribing
- Smoking and Lung Cancer Associations
- New Therapeutic Options for Metastatic Castration-Resistant Prostate Cancer: The Latest Data From ASCO 2008
POLL
A new bill in Congress would send trained clinicians into doctors’ offices with independent data about the relative benefits, risks, and costs of drugs; some research suggests that such "academic detailing" reduces potential prescribing bias from the influence of drug company reps. What effect do you think such a program would have?